https://orcid.org/0000-0002-2173-1027
References
- Urru SAM, Maines E, Campomori A, Soffiati M. Safety of Sars-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance. Hum Vaccines Immunother. 2021;17:4112–2. doi:10.1080/21645515.2021.1943992.
- Saborido-Fiaño R, Martinón-Torres N, Crujeiras-Martinez V, Couce ML, Leis R. Reply letter to ‘safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance’. Hum Vaccines Immunother. 2021;17:4115–16. doi:10.1080/21645515.2021.1959149.
- Gallo G; Mel R; Ros E and Filia A, editors. 2019. Guida alle controindicazioni alle vaccinazioni (aggiornamento 2018). Roma (Italy): Istituto Superiore di Sanità. (Rapporti ISTISAN 19/3).
- Excipients in the labelling and package leaflet of medicinal products for human use. Annex to the European Commission guideline. EMA/CHMP/302620/2017. [accessed 2022 Feb 01]. https://www.ema.europa.eu/en/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human_en.pdf .
- Weser E, Sleisenger MH. Metabolism of circulating disaccharides in man and the rat. J Clin Invest. 1967;46:499–505. doi:10.1172/JCI105552.
- Izquierdo-García E, Moreno-Villares JM, León-Sanz M. Sweeteners in hereditary fructose intolerance patients. Acta Pediátrica Esp. 2014;72:15–23.
- Ali M, Rellos P, Cox TM. Hereditary fructose intolerance. J Med Genet. 1998;35:353. doi:10.1136/jmg.35.5.353.
- Maiorana A, Sabia A, Corsetti T, Dionisi-Vici C. Safety of vaccines administration in hereditary fructose intolerance. Orphanet J Rare Dis. 2020;15:274. doi:10.1186/s13023-020-01552-z.
- Izquierdo-García E, Escobar-Rodríguez I, Moreno-Villares JM, Iglesias-Peinado I. Social and health care needs in patients with hereditary fructose intolerance in Spain. Endocrinol Diabetes Nutr (Engl Ed). 2020;67:253–62. doi:10.1016/j.endinu.2019.06.005.